


## Visistar<sup>®</sup> VEGFR2 Targeted Ultrasound Contrast Agent

Catalog Number: VS-102 (1 x 0.3 ml vial)

Visistar VEGFR2 is indicated for ultrasound molecular imaging of tumor angiogenesis, targeted specifically to the VEGFR2 receptor on the endothelium, at ultrasound frequencies in 1-15 MHz range. Contrast imaging settings such as pulse inversion or CPS must be enabled on the ultrasound scanner for optimal contrast sensitivity. The agent remains acoustically active for 5-15 minutes, depending on the administered dose. Optimal dosages vary with application. Please contact Targeson technical support for protocol assistance.



Molecular Imaging of tumor angiogenesis. C57/Bl6 mice were inoculated with MC-38 (syngeneic colon carcinoma) cells to form a subcutaneous solid tumor on the hind limb. Image A is a B-mode image showing ovoid tumor, with skeletal muscle below and to left. Image B acquired at 8 minutes after administration of Visistar VEGFR2 shows diffuse contrast accumulation (presented in shades of orange) throughout the tumor, with minimal accumulation in the adjacent muscle. Image C is an image of the same tumor acquired 7 minutes after administration of a control microsphere shows negligible accumulation of the agent. Images were acquired at 14 MHz in CPS with Sequia<sup>®</sup> 512 and are courtesy of Dr. Sasha Klibanov (University of Virginia).

- **Applicable for ultrasound imaging of tumor angiogenesis**
- **Targeted to specifically to the VEGFR-2 receptor**
- **Compatible with most ultrasound scanners**
- **Easy to use, ready to administer directly from vial**
- **Conveniently stable for 1 full working day after septum penetration**
- **Ample time to acquire images with vascular persistence of 15-20 minutes**
- **Conveniently packaged for adequate imaging of 10 mice per vial**

FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS. Targeson makes no representations and extends no warranties of any kind, and expressly disclaims all implied warranties of merchantability and of fitness for a particular purpose or use. Targeson disclaims all warranties of noninfringement with respect to any third party rights and title, including patent rights, in the materials. Use of this product is governed by the Targeson terms and conditions agreement, available at [www.targeson.com](http://www.targeson.com). Targestar<sup>®</sup>, Targosphere<sup>®</sup> and Visistar<sup>®</sup> are registered trademarks of Targeson. The VEGFR2 ligand is produced by Sibtech, Inc. Sequoia<sup>®</sup> is a registered trademark of Siemens.